Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Neuraxpharm Sweden AB
AB
Active
Org 5592759269
Danderyd
Wholesale of pharmaceutical and medical goods
· NACE 4646
Est. 2020
5-9 employees
Watchlist
Share
Sweden
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Neuraxpharm Sweden AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
13M
25M
38M
51M
2M
2021
4M
2022
12M
2023
44M
2024
EBITDA
SEK millions
0M
-0M
-1M
-1M
-1M
-3M
2021
-5M
2022
-3M
2023
-1M
2024
Income statement
SEK thousands
Item
2021
2022
2023
2024
Revenue
1 689
3 784
11 836
43 878
Staff expenses
—
—
—
—
EBITDA
−3 117
−4 532
−3 469
−1 057
Depreciation & amort.
−3
−8
−183
−115
EBIT
−3 120
−4 540
−3 652
−1 172
Net financials
—
−2
−134
−134
Profit before tax
−3 121
−4 542
−3 787
−1 306
Tax
−0
−0
−0
−0
Net profit
−3 121
−4 542
−3 787
−1 306
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
Total assets
2 880
4 565
35 157
34 347
Equity
1 897
2 539
3 469
22 924
Long-term debt
0
0
0
0
Short-term debt
983
2 026
31 688
11 423
Total debt
983
2 026
31 688
11 423
Financial ratios
5-year trend
EBITDA margin
-2.4%
This company
15.8%
Market median
-115% vs market
2021
2024
Equity ratio
66.7%
This company
38.2%
Market median
+75% vs market
2021
2024
Return on equity
-5.7%
This company
18.4%
Market median
-131% vs market
2021
2024
Net profit margin
-3.0%
This company
8.1%
Market median
-137% vs market
2021
2024
Asset turnover
1.28×
This company
1.12×
Market median
+14% vs market
2021
2024
Debt / equity
0.50×
This company
0.62×
Market median
+19% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-12-31
View
PDF
More on Neuraxpharm Sweden AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
